Thirty-four patients with HER2-low breast cancer were enrolled at data cutoff (12 October 2018), with a median age of 56 years (range 33–75) and a median number of prior cancer regimens of 8 (2–18) [32]. This evidence concerns the gene ERBB2 and breast carcinoma.